A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria
Goldfarb DS, Modersitzki F, Asplin JR
Published in Clinical Journal of the American Society of Nephrology
Methodology
Randomised, double-blind, placebo-controlled trial; 3.6 g/day granulate for 28 days; two consecutive 24-hour urine collections at baseline, day 28 and day 56 with replicated diet.
Key Findings
20 calcium stone formers with idiopathic hyperoxaluria (>40 mg/day) were randomised 1:1 to 3.6 g/day of Oxadrop, a four-species lactic acid bacteria mix, or placebo for 28 days with diet replicated at each collection. There was no effect: mean 24-hour urinary oxalate was 73.9 mg at baseline and 72.7 mg after placebo, versus 59.1 mg and 55.4 mg with Oxadrop. The preparation was well tolerated, with mild constipation in three participants on active treatment.
Conclusions
Probiotic lactic acid bacteria did not reduce urinary oxalate excretion in idiopathic hyperoxaluria.
Limitations
Only 10 participants per arm and a 28-day treatment window, using urinary oxalate as a surrogate rather than stone recurrence; underpowered to exclude a small effect.
Supplements Studied
In this randomized, placebo-controlled trial, Oxadrop did not reduce urinary oxalate excretion in participants with idiopathic hyperoxaluria.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.